Bizarre Patents
Combination Beverage Container and Spittoon
A combination beverage container and spittoon includes a bottom portion including outer wall and a first inner wall defining a spittoon space.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128660 | DIAGNOSIS OF RESTENOSIS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION The present invention relates to compounds, compositions, methods and/or kits for determining and/or predicting and/or diagnosing and/or treating restenosis in a patient.... | 05/24/2012 |
| 20120128783 | Compositions and methods for delivery of frozen particle adhesives Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehi... | 05/24/2012 |
| 20120128659 | AGENTS CAPABLE OF DOWNREGULATING AN MSF-A - DEPENDENT HIF-1ALPHA AND USE THEREOF IN CANCER TREATMENT Methods and pharmaceutical compositions for the treatment of cancer or acute ischemia are provided. Also provided are methods of identifying agents capable of preventing the formation of or dissociating the MSF-A-HIF-1alpha protein complex, and methods of determining th... | 05/24/2012 |
| 20120128657 | SYNTHETIC MACROCYCLIC COMPOUNDS AND METHODS FOR TREATING CANCER Disclosed herein are macrocyclic compounds that are effective to inhibit cell migration. In one embodiment, the compounds have the structure: or any pharmaceutically acceptable salt or solvate thereof, wherein: m is 0 or 1; R1, R2 and R3 05/24/2012 | |
| 20120128763 | LUBRICANT FOR THE OCULAR SURFACE A formulation has been developed for treatment of the symptoms of dry eye which incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear and eyedrop as well as stabilize the eyedrop. The improved performance of ... | 05/24/2012 |
| 20120128752 | MULTI-PHASE MICROPARTICLES AND METHOD OF MANUFACTURING MULTI-PHASE MICROPARTICLES The invention relates to a method of manufacturing multi-phase microparticles. The method comprises dissolving at least three different polymers in a volatile organic solvent to obtain a first solution. The first solution comprises at least two cloud points, wherein the... | 05/24/2012 |
| 20120130300 | Therapeutic Methods Using Controlled Delivery Devices Having Zero Order Kinetics An injectable or implantable medical device having orifice(s) on the surface that release an active agent with zero-order release kinetics is described herein. The device is a hollow matrix of any size or shape, which can be made from both metal and non-metal surfaces. ... | 05/24/2012 |
| 20120128658 | RAGE G82S-RELATED METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS This invention provides methods, compositions and articles of manufacture for inhibiting the onset of and treating inflammatory disorders such as rheumatoid arthritis. The instant invention is based on the blockade of RAGE G82S function.... | 05/24/2012 |
| 20120128656 | Vaccine compositions and methods The present invention relates to pharmaceutical vaccine compositions comprising at least one vaccine antigen together with living immune cells. These immune cells include at least a portion of activated T-cells and act as an adjuvant. Methods for using these pharmaceuti... | 05/24/2012 |
| 20120107408 | PHARMACEUTICAL MICROPARTICLES Microparticles consisting of (a) a matrix with a mixture of (a1) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a pharmaceutical active ingredient distributed in the matrix, and (c) in addition at le... | 05/03/2012 |
| 20120107301 | METHOD OF TREATING AUTOIMMUNE DISEASE BY INDUCING ANTIGEN PRESENTATION BY TOLERANCE INDUCING ANTIGEN PRESENTING CELLS Antibodies to antigen presenting cells may be utilized to interfere with the interaction of the antigen presenting cell and immune cells, including T cells. Peptides may be linked to said antibodies thereby generating an immune response to such peptides. Preferably pept... | 05/03/2012 |
| 20120107315 | Predicting progression to advanced age-related macular degeneration using a polygenic score The present invention relates to methods for identifying individuals with intermediate age-related macular degeneration (AMD) who possess a greater risk of progression to advanced AMD, using a polygenic score calculated based on the results of genome-wide gene associati... | 05/03/2012 |
| 20120107306 | ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and me... | 05/03/2012 |
| 20120082658 | Methods for the Treatment of Allergic Diseases The present invention is directed generally to a TLR8 agonist VTX-378, for use in the treatment or prevention of allergic diseases, including allergic rhinitis.... | 04/05/2012 |
| 20120082659 | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations Disclosed are compositions and methods related to new targets for cancer treatment.... | 04/05/2012 |
| 20120082715 | Stabilized products, processes and devices for preparing the same A composition comprising a glassified, stabilized particle preparation having a low water activity (between about 0.1 and 0.9) is provided. The preparations provide improved products with enhanced storage stability, less expensive cost of processing, and extended shelf ... | 04/05/2012 |
| 20120082660 | ANTI-TNF INDUCED APOPTOSIS (ATIA) DIAGNOSTIC MARKERS AND THERAPIES The invention features diagnostic and therapeutic methods and compositions featuring Anti-TNF Induced Apoptosis (ATIA). ATIA is useful as a diagnostic marker for cancer, in particular for glioblastoma. ATIA is also a therapeutic target in diseases such as cancer. The in... | 04/05/2012 |
| 20120070427 | VORTEX-INDUCED SILK FIBROIN GELATION FOR ENCAPSULATION AND DELIVERY The present invention provided for a novel process of forming silk fibroin gels, and controlling the rate of β-sheet formation and resulting hydrogelation kinetics, by vortex treatment of silk fibroin solution. In addition, the vortex treatment of the present invention... | 03/22/2012 |
| 20120070426 | PEPTIDE-BASED PASSIVE IMMUNIZATION THERAPY FOR THE TREATMENT OF ATHEROSCLEROSIS The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or ... | 03/22/2012 |
| 20120070368 | Methods of Using C-Met Modulators Disclosed are methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt thereof, in combination with gemcitabine (GEM), or a pharmaceutically acceptable salt t... | 03/22/2012 |
| 20120070369 | HIF INHIBITORS AND USE THEREOF The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.... | 03/22/2012 |
| 20120070404 | Increasing cancer patient survival time by administration of dithio-containing compounds The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or... | 03/22/2012 |
| 20120070406 | THERAPEUTIC PROTEIN COMPOSITIONS HAVING REDUCED IMMUNOGENICITY AND/OR IMPROVED EFFICACY The present invention provides methods for reducing and/or evaluating the immunogenic potential of a therapeutic protein preparation. The present invention further provides pharmaceutical compositions of therapeutic proteins and methods of treatment with the same, the c... | 03/22/2012 |
| 20120052057 | METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS The present invention relates to a method for identifying responders to a blockade of integrin receptors, as well as to a method for determining responsiveness to a treatment involving with said blockade in a patient in need of such treatment. Furthermore, the present i... | 03/01/2012 |
| 20120052110 | METHODS AND COMPOSITIONS FOR PROMOTING WOUND HEALING Provided herein are compositions and methods that inhibit expression of Adam12 gene products, such as ADAM12 mRNA and/or ADAM12 polypeptides, as a therapeutic approach for the treatment of, or promotion of healing of, wounds.... | 03/01/2012 |
| 20120052045 | Compositions and methods for modulating ischemic injury The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating i... | 03/01/2012 |
| 20120052058 | METHODS OF MANAGING THE BLOOD COAGULATION AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO The disclosure relates to methods of managing blood coagulation and pharmaceutical compositions related thereto. In certain embodiments, the disclosure relates to methods of managing the coagulation of blood in a patient undergoing surgery comprising administering combi... | 03/01/2012 |
| 20120052065 | METHODS OF TREATMENT USING CTLA4 MUTANT MOLECULES The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of... | 03/01/2012 |
| 20120045448 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS Compounds of the disclosure provide compositions, which are effective for prophylaxis and treatment of diseases or disorders, such as cell-proliferation, angiogenesis, or apoptosis mediated diseases. The disclosure encompasses compounds, analogs, prodrugs, metabolites, ... | 02/23/2012 |
| 20120045487 | MULTIPHASIC MICROFIBERS FOR SPATIALLY GUIDED CELL GROWTH A multiphasic microfiber for a three-dimensional tissue scaffold and/or cellular support is provided in one aspect that includes at least one biocompatible material. The multiphasic microfiber optionally has a first phase and at least one distinct additional phase and i... | 02/23/2012 |
| 20120045432 | B LYMPHOCYTE STIMULATOR ASSAYS The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host ... | 02/23/2012 |
| 20120045429 | Methods and Agent for Modulating the RNA Polymerase II-Histone Surface The present invention relates to the identification of an intranucleosomal DNA loop formed during transcription through a nucleosome and use of the same to identify an agent that modulates the RNA Polymerase II-histone surface.... | 02/23/2012 |
| 20120045517 | TREATMENT OF CELIAC DISEASE WITH IgA A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating a... | 02/23/2012 |
| 20120045431 | METHOD OF STABILIZING AND STERILIZING PEPTIDES OR PROTEINS The present invention provides a method for sterilizing a protein-containing bioerodible implant. The sterilization is accomplished using β-radiation, or high energy electrons. Following sterilization the implant can be used in a variety of methods for the sustained re... | 02/23/2012 |
| 20120045430 | DENDRIMER-LIKE MODULAR DELIVERY VECTOR Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, ca... | 02/23/2012 |
| 20120039871 | METHODS AND COMPOSITIONS FOR ANTIBODY THERAPY Methods and materials are provided for selecting and/or treating a subject based on a FcγRIIA polymorphism, or a FcγRIIB polymorphism, or both an FcγRIIA polymorphism and a FcγRIIB polymorphism, for treatment with a therapy including an antibody therapy such as ritu... | 02/16/2012 |
| 20120039907 | POLYPEPTIDES INCLUDING MODIFIED CONSTANT REGIONS Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having increased binding affinity for an FcγR, which processes comprise modifying the polypeptides by substitution of the amino acid at position 268 of a human IgG CH2 region for a non-native... | 02/16/2012 |
| 20120039868 | Biomarkers for Graft Rejection Methods are disclosed for diagnosing rejection in a transplanted subject, monitoring rejection in a transplanted subject at risk thereof, preventing, inhibiting, reducing or treating rejection in a transplanted subject, or identifying agents for use in the prevention, i... | 02/16/2012 |
| 20120039866 | METHODS OF TREATING PAIN The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activi... | 02/16/2012 |
| 20120039867 | Immune System Function in Conditions Characterized by Elevated Double Strand Breaks Methods and compositions for improving immune system function are provided. These methods find particular use in improving immune system function in individuals with a condition in which naïve lymphocytes comprise elevated amounts of DNA double strand breaks (DSB), for... | 02/16/2012 |
